Development and evaluation of the oligonucleotide ligation assay (OLA) for the detection of drug resistance mutations in HIV-2 patients on antiretroviral therapy

The naturally resistance of HIV-2 to non-nucleoside reverse transcriptase inhibitors and T-20, as well as its reduced susceptibility to some protease inhibitors makes the nucleoside reverse transcriptase inhibitors (NRTI) crucial in HIV-2 therapy. Hence, early detection of resistance mutations to NRTI is important to explain treatment failures and to guide therapy.

HIV-2 OLA was developed for the Q151M and M184V mutations using a set of 3 oligonucleotide probes for each mutation. 90 HIV-2 samples from Guinea Bissau, the Gambia and Sweden were amplified, sequenced and evaluated in OLA.

OLA sensitivity was 100% for Q151M and 98% for M184V. Concordance between sequencing and OLA was 99% and 97% for the Q151M and M184V mutations respectively.

OLA was successfully developed for major HIV-2 mutations. Its ease-of-use, economical nature and high concordance with sequencing makes it more appropriate for use in resource-poor settings.

Affiliations

1. Medical Research Council (MRC), Banjul, The Gambia
   • Sabelle Jallow
   • , Steve Kaye
   • , Hilton Whittle
   •  & Sarah Rowland-Jones
2. Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium
   • Sabelle Jallow
   • , Guido Vanham
   •  & Wouter Janssens
3. Department of Virology, Swedish Institute for Infectious Disease Control, Solna, Sweden
   • Eleanor Brandin
   •  & Jan Albert

Corresponding author

Correspondence to Sabelle Jallow.

Reprints and Permissions